Volastra Therapeutics

Volastra Therapeutics is hiring a Clinical Research Associate (CRA) to join our clinical operations team and support the execution of our oncology clinical trials. This role will be involved across trial start-up, maintenance, and close-out activities, contributing to the day-to-day operations of our clinical programs. We’re looking for someone who is detail-oriented, proactive, and eager to grow within a collaborative, fast-paced biotech environment.   https://lnkd.in/eSCmBbaZ   #Hiring #ClinicalResearch #ClinicalTrials #LifeSciences #BiotechCareers #Oncology #VolastraTherapeutics #NowHiring #NYCJobs

Meet Cayley Gehnrich, Volastra's HR & Operations Manager. With a strong background in startups, Cayley plays a key role in shaping Volastra’s collaborative culture and supporting our growing team. Read more about what makes working in biotech so energizing for her below. #CareerJourneys #VolastraCareers #Oncology

Congratulations to our partners at Tailor Bio on their recent publication, which establishes the utility of their proprietary chromosomal instability (CIN) signatures in predicting resistance to cancer chemotherapies.    This publication represents major step forward for their platform and we look forward to our continued collaboration applying Tailor’s CIN signatures to potentially expand the use of KIF18A inhibitors across a broader array of tumor types.   #NatureGenetics #TailorBio #PrecisionOncology #KIF18A #OvarianCancer #CancerResearch

A proud moment at #ASCO25: data from the dose escalation portion of our Phase I/II study for our novel #KIF18A inhibitor, VLS-1488, earned a spot at the podium during the Development Therapeutics – Molecular Targeted Agents and Tumor Biology session. This milestone reflects the momentum behind #KIF18A inhibition and the dedication of our team and partners to advancing treatments for hard-to-treat cancers. Learn more here: https://lnkd.in/e69URRsv

MD Anderson is sharing 120+ studies at #ASCO25. Five stand out for their potential to transform care for thyroid, colorectal, ovarian and rare blood cancers. From innovative therapies to novel drug combos, these findings could help shape the next generation of treatment. See what's in store. #EndCancer

We’re thrilled to welcome David Southwell, to the Volastra team as Chief Executive Officer! David brings over 30 years of experience as a seasoned biotech leader with a proven track record of guiding companies through critical phases of growth and innovation. His leadership comes at an exciting time for Volastra as we advance our pipeline and continue our mission to develop novel therapies for hard-to-treat cancers. Learn more about David and read the full press release here: https://lnkd.in/ej9Jf8JU

Our Chief Medical Officer and Head of R&D, Scott Drutman MD PhD, spoke with Endpoints News this week to share insights from our first-in-human #KIF18A data being presented at #ASCO2025. Grateful to our team, collaborators, and the patients who made this research possible.   #Volastra #Chromosomalinstability #Biotech #ClinicalDevelopment

Volastra is thrilled to share encouraging initial data from the dose escalation portion of our Phase I/II trial of our novel #KIF18A inhibitor, VLS-1488, at #ASCO2025 in Chicago. More details here: https://lnkd.in/dXe3esk7

We’re hiring! Join us at Volastra Therapeutics as we continue advancing the fight against cancer through innovative science and a collaborative, mission-driven culture. We’re excited to share two new opportunities on our growing team: Development Project Manager, Oncology (Sr. Manager / Associate Director): Play a key role in driving the execution of our clinical-stage oncology programs. We're looking for a collaborative and detail-oriented project manager with hands-on experience in early-stage oncology development and cross-functional coordination. Learn more here: https://lnkd.in/eqWngmDx Associate Director / Director, Analytical Development: Help lead analytical method development and product characterization efforts that are essential to our drug development pipeline. This role is ideal for a seasoned scientist with deep experience in small molecule development, method validation, and regulatory strategy. Learn more here: https://lnkd.in/eHq-VEJx If you're ready to bring your expertise to a mission-driven team committed to making a real impact in oncology, we’d love to hear from you!

Today, on World Ovarian Cancer Day, we’re committed to raising awareness and remembering those behind these sobering statistics - the patients, families, and communities affected by ovarian cancer. Their experiences motivate our work at Volastra and fuel our commitment to delivering new treatment options for this devastating disease. #NoWomanLeftBehind #WOCD2025 #WorldOvarianCancerDay